Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG617

—

4c4d5f94-ab4c-573d-a3ee-abfc430e4319

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.292
  • IL6_JAK_STAT3_SIGNALING+0.247
  • INFLAMMATORY_RESPONSE+0.241
  • ALLOGRAFT_REJECTION+0.225
  • UV_RESPONSE_DN+0.220
  • INTERFERON_GAMMA_RESPONSE+0.196
  • INTERFERON_ALPHA_RESPONSE+0.189
  • MYOGENESIS+0.159
  • KRAS_SIGNALING_UP+0.149
  • APICAL_SURFACE+0.125

Top 10 suppressed

  • G2M_CHECKPOINT-0.410
  • E2F_TARGETS-0.369
  • MITOTIC_SPINDLE-0.349
  • MYC_TARGETS_V2-0.304
  • MTORC1_SIGNALING-0.281
  • CHOLESTEROL_HOMEOSTASIS-0.256
  • DNA_REPAIR-0.254
  • UV_RESPONSE_UP-0.184
  • GLYCOLYSIS-0.174
  • PROTEIN_SECRETION-0.151

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG490
mng-umap@100
——0.863
2MNG537
mng-umap@100
——0.826
3MNG915
mng-umap@100
——0.816
420040019.LumA
breast-umap@18
—A0.812
5TCGA-BH-A0B2-01A-11R-A10J-07
breast-umap@18
—A0.811
6SRR1797234
lung-landscapes@6
—cohortMD20.801
7SRR10899975
melanoma-umap@29
——0.799
8SRR8518288
breast-umap@18
—A0.796
9TCGA-CV-A6K0-01B-21R-A31N-07
head-neck@1
——0.795
10DRR168573
bladder-landscape@3
——0.794

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.292Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.247Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.241Idelalisib— uncovered
ALLOGRAFT_REJECTION0.225Idelalisib— uncovered
UV_RESPONSE_DN0.220Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.196Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.189Inavolisib— uncovered
MYOGENESIS0.159Inavolisib— uncovered
KRAS_SIGNALING_UP0.149Inavolisib— uncovered
APICAL_SURFACE0.125Temsirolimus— uncovered
TGF_BETA_SIGNALING0.122Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.078Inavolisib— uncovered
COAGULATION0.075Binimetinib— uncovered
WNT_BETA_CATENIN_SIGNALING0.071Inavolisib— uncovered
ADIPOGENESIS0.067Inavolisib— uncovered
FATTY_ACID_METABOLISM0.060Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.053Inavolisib— uncovered
IL2_STAT5_SIGNALING0.038Idelalisib— uncovered
KRAS_SIGNALING_DN0.036Remibrutinib— uncovered
APICAL_JUNCTION0.033Inavolisib— uncovered